



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 08/444,791-Conf. #5613 |
| | | | | Filing Date | May 19, 1995 |
| | | | | First Named Inventor | Manfred Brockhaus |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | R. Schwadron |
| Sheet | 1 | of | 1 | Attorney Docket Number | 01017/40451C |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | | | | | | |


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | | |
| P31 | | Official Communication relating to an Opposition in EP Application No. 99 100 703.0. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|--|--------------------|--------|
| Examiner Signature | | Date Considered | 3/1/07 |
|-----------------------|--|--------------------|--------|



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 08/444,791-Conf. #5613 | |
| | | | Filing Date | May 19, 1995 | |
| | | | First Named Inventor | Brockhaus | |
| | | | Art Unit | 1644 | |
| | | | Examiner Name | R. Schwadron, Ph.D. | |
| Sheet | 1 | of | 8 | Attorney Docket Number | 01017/40451C |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|----------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. | Document Number Number-Kind Code ² (# known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| VS | A5 | 08/478,995 | N/A | Lauffler, Leander et al. | |
| | A6 | 2003/064480 | 04-03-2003 | Lauffler, Leander et al. | |
| | A7 | 4,593,002 | 01-11-1982 | Dulbecco | |
| | A8 | 4,675,285 | 09-19-1984 | Clark et al. | |
| | A9 | 4,729,326 | 03-08-1988 | Richter | |
| | A10 | 4,769,326 | 09-06-1988 | Rutler | |
| | A11 | 4,894,439 | 01-16-1990 | Dorin et al. | |
| | A12 | 4,912,044 | 03-27-1990 | Jacob et al. | |
| | A13 | 4,935,233 | 06-19-1990 | Bell et al. | |
| | A14 | 4,963,354 | 10-06-1990 | Shepard et al. | |
| | A15 | 4,965,271 | 10-23-1990 | Mandell et al. | |
| | A16 | 5,055,447 | 10-08-1991 | Palladino et al. | |
| | A17 | 5,073,627 | 12-17-1991 | Curtis et al. | |
| | A18 | 5,075,222 | 12-24-1991 | Hannum et al. | |
| | A19 | 5,098,702 | 03-24-1992 | Zimmerman et al. | |
| | A20 | 5,098,833 | 03-24-1992 | Lasky et al. | |
| | A21 | 5,118,500 | 06-02-1992 | Hanel et al. | |
| | A22 | 5,136,021 | 08-04-1992 | Dembinski et al. | |
| | A23 | 5,155,027 | 10-13-1992 | Sledziewski et al. | |
| | A24 | 5,211,395 | 06-29-1993 | Gero | |
| | A25 | 5,211,945 | 05-18-1993 | Wallach et al. | |
| | A26 | 5,225,538 | 07-06-1993 | Capon et al. | |
| | A27 | 5,258,498 | 11-02-1993 | Huston et al. | |
| | A28 | 5,264,416 | 11-23-1993 | Park et al. | |
| | A29 | 5,270,038 | 12-14-1993 | Klimpel et al. | |
| | A30 | 5,336,603 | 08-09-1994 | Capon et al. | |
| | A31 | 5,350,683 | 09-27-1994 | Sims et al. | |
| | A32 | 5,359,032 | 10-25-1994 | Dayer et al. | |
| | A33 | 5,447,851 | 09-05-1995 | Beutler et al. | |
| | A34 | 5,455,165 | 10-03-1995 | Capon et al. | |
| | A35 | 5,478,925 | 12-26-1995 | Wallach et al. | |
| | A36 | 5,512,544 | 04-30-1996 | Wallach et al. | |
| | A37 | 5,514,582 | 05-07-1996 | Capon et al. | |
| | A38 | 5,599,905 | 02-04-1997 | Mosley et al. | |
| | A39 | 5,605,690 | 02-25-1997 | Jacobs et al. | |
| | A40 | 5,610,279 | 03-11-1997 | Brockhaus et al. | |
| | A41 | 5,633,145 | 05-27-1997 | Feldmann et al. | |
| | A42 | 5,639,597 | 06-17-1997 | Lauffer et al. | |
| | A43 | 5,695,953 | 12-09-1997 | Wallach et al. | |
| | A44 | 5,705,364 | 01-06-1998 | Etcheverry et al. | |
| | A45 | 5,712,155 | 01-27-1998 | Smith et al. | |
| | A46 | 5,721,121 | 02-24-1998 | Etcheverry et al. | |
| | A47 | 5,808,029 | 09-15-1998 | Brockhaus et al. | |
| | A48 | 5,811,261 | 09-22-1998 | Wallach et al. | |
| | A49 | 5,863,786 | 01-26-1999 | Feldmann et al. | |
| | A50 | 5,945,397 | 08-31-1999 | Smith et al. | |
| Examiner Signature | | | | Date Considered | 3/1/07 |



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 08/444,791-Conf. #5613 | |
| | | | Filing Date | May 19, 1995 | |
| | | | First Named Inventor | Brockhaus | |
| | | | Art Unit | 1644 | |
| | | | Examiner Name | R. Schwadron, Ph.D. | |
| Sheet | 2 | of | 8 | Attorney Docket Number | 01017/40451C |

| | | | | | |
|-----|-----|-----------|------------|------------------|--|
| 131 | A51 | 5,981,701 | 11-09-1999 | Wallach et al. | |
| | A52 | 6,143,866 | 11-07-2000 | Brewer et al. | |
| | A53 | 6,165,476 | 12-26-2000 | Strom et al. | |
| | A54 | 6,201,105 | 03-13-2001 | Smith et al. | |
| | A55 | 6,221,675 | 04-24-2001 | Hauptmann et al. | |
| | A56 | 6,271,346 | 08-07-2001 | Hauptmann et al. | |
| | A57 | 6,294,352 | 09-25-2001 | Hauptmann et al. | |
| | A58 | 6,541,610 | 04-01-2003 | Smith | |
| | A59 | 6,541,620 | 04-01-2003 | Brewer et al. | |
| | A60 | 6,572,852 | 06-03-2003 | Smith et al. | |
| | A61 | RE 36,755 | 06-27-2000 | Smith et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|----------|--|--------------------------------|---|---|----------------|
| 131 | B13 | AU 58976 | 01-24-1991 | Synergen, Inc. | | |
| | B14 | EP 120694 | 10-03-1984 | Boss et al. | | |
| | B15 | EP 227110 | 07-01-1987 | Satoshi et al. | | |
| | B16 | EP 230574 | 08-05-1987 | Ruddle | | |
| | B17 | EP 269455 | 06-01-1988 | Ikeyama et al. | | |
| | B18 | EP 314317 | 05-03-1989 | Capon et al. | | |
| | B19 | EP 325262 | 07-26-1989 | Seed | | |
| | B20 | EP 414178 | 02-27-1991 | Seed | | |
| | B21 | EP 447563 | 03-20-1991 | Brockhaus et al. | | |
| 131 | B22 | EP 460846 | 12-11-1991 | Sims et al. | | |
| | B23 | EP 471701 | 02-26-1992 | Lamarie et al. | | |
| 131 | B24 | EP 526452 | 02-10-1993 | Capon et al. | | |
| | B25 | EP 526905 | 02-10-1993 | Wallach et al. | | |
| | B26 | EP 568925 | 11-10-1993 | Wallach et al. | | |
| | B27 | EP 606869 | 07-20-1994 | Wallach et al. | | |
| | B28 | GB 2,218,101A | 10-08-1989 | Dayer and Seckinger | | |
| | B29 | GB 2 246 569 | 02-05-1992 | Feldman et al. | | |
| | B30 | JP 02-154695 | 06-14-1990 | Brockhaus et al. | | |
| | B31 | JP 01-293024 | 12-24-1986 | Yojiro et al. | | |
| 131 | B32 | WO 91/02078 | 02-21-1991 | Rathjen et al. | | |
| | B33 | WO 91/08298 | 12-13-1991 | Capon et al. | | |
| | B34 | WO 91/17184 | 11-14-1991 | Carter | | |
| | B35 | WO 92/08495 | 05-29-1992 | Gillies | | |
| | B36 | WO 92/13095 | 08-06-1992 | Carmichael et al. | | |
| | B37 | WO 93/07863 | 04-29-1993 | Mullarkey | | |
| | B38 | WO 93/19777 | 10-14-1993 | Smith | | |
| | B39 | WO 94/06476 | 03-31-1994 | Smith et al. | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 7/1/02 |
|--------------------|--|-----------------|--------|

Crossed out documents
not in compliance
with 37 CFR 1.48 (a)(3)



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 08/444,791-Conf. #5613 |
| | | | | Filing Date | May 19, 1995 |
| | | | | First Named Inventor | Brockhaus |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | R. Schwadron, Ph.D. |
| Sheet | 3 | of | 8 | Attorney Docket Number | 01017/40451C |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| MJS | C31 | ABRAHAM et al., p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: $\Delta\Delta\Delta\Delta$ JAMA, 19:1531-1538 (1997) | |
| | C32 | ABRAHAM et al., Lenercept (p55 Tumor Necrosis Factor Receptor Fusion Protein) In Severe Sepsis and Early Septic Shock: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial With 1,342 Patients, Crit Care Med., 29:503-510 (2001) | |
| | C33 | AGGARWAL et al., Characterization of Receptors for Human Tumour Necrosis Factor and Their Regulation by γ -Interferon, Nature, 318:665-667 (1985) | |
| | C34 | AGGARWAL et al., Induction of Receptors for Tumor Necrosis Factor- α by Interferons Is Not a Major Mechanism for Their Synergistic Cytotoxic Response, J. Biol. Chem., 262:10000-10007 (1987) | |
| | C35 | AGGARWAL et al., Human tumour necrosis factors: structure and receptor interactions, in Tumor necrosis factor and related cytotoxins, pp. 39-51, (Ciba Foundation symposium 131), Wiley, Chichester (1987) | |
| | C36 | ARENZANA-SEISDEDOS et al., Immunoregulatory Mediators in the Pathogenesis of Rheumatoid Arthritis, Scand. J. Rheumatol., Supplement 66:13-17 (1987) | |
| | C37 | ARUFFO et al., Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System, Proc. Natl. Acad. Sci. USA, 84:8573-8577 (1987). | |
| | C38 | ASHKENAZI et al., Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin, Proc. Natl. Acad. Sci., U.S.A. 88:10535-10539 (1991) | |
| | C39 | AYALA, Modern Genetics, Benjamin/Cummings, Publ. Co., Menlo Park CA, p. 45, (1980) | |
| | C40 | BAGLIONI et al., Binding of Human Tumor Necrosis Factor to High Affinity Receptors on HeLa and Lymphoblastoid Cells Sensitive to Growth Inhibition, J. Biol. Chem., 260:13395-13397 (1985) | |
| | C41 | BENJAMINI et al., Antibody Structure, in Immunology: A Short Course, 3rd ed., Wiley-Liss New York, 61-69 (1996) | |
| | C42 | BRANELLEC et al., TNF: Antitumoral Agent at the Border Lines of Immunity and Inflammation, Path. Biol., 39:230-239 (1991) | |
| | C43 | BROCKHAUS et al., Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies, Proc. Natl. Acad. Sci. USA, 87:3127-3131 (1990) | |
| | C44 | CARTER et al., Purification, Cloning, Expression and Biological Characterization of an Interleukin-1 Receptor Antagonist Protein, Nature, 344:633-638 (1990) | |
| | C45 | CARPENTER et al., Epidermal Growth Factor, J. Biol. Chem., 265:7709-7712 (1990) | |
| | C46 | CARPENTER, Receptors For Epidermal Growth Factor And Other Polypeptide Mitogens, Ann. Rev. Biochem., 56:881-914 (1987) | |
| | C47 | CASADEI et al., Expression and Secretion of Aequorin as a Chimeric Antibody by Means of a Mammalian Expression Vector, Proc. Natl. Acad. Sci., U.S.A. 87:2047-2051 (1990) | |
| | C48 | COFFMAN et al., The Role of Helper T Cell Products in Mouse B Cell Differentiation and Isotype Regulation, Immunol. Rev., 102:5-28 (1988) | |
| | C49 | CREASEY et al., A High Molecular Weight Component of the Human Tumor Necrosis Factor Receptor is Associated With Cytotoxicity, Proc. Natl. Acad. Sci. USA, 84:3293-3297 (1987) | |

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 3/1/02 |
|--------------------|--|-----------------|--------|



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO | | | | Complete if Known | |
| | | | | Application Number | 08/444,791-Conf. #5613 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Filing Date | May 19, 1995 |
| | | | | First Named Inventor | Brockhaus |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | R. Schwadron, Ph.D. |
| Sheet | 4 | of | 8 | Attorney Docket Number | 01017/40451C |

| | | | |
|---|-----|--|--|
| ✓ | C50 | DAYER, Chronic Inflammatory Joint Diseases: Natural Inhibitors of Interleukin 1 and Tumor Necrosis Factor α , J. Rheumatol, 18 (Suppl. 27): 71-75 (1991) | |
| | C51 | DOWER et al., Human Cytokine Receptors, J. Clin. Immunol., 10:289-299 (1990) | |
| | C52 | EISENBERG et al., Primary Structure and Functional Expression From Complementary DNA of a Human Interleukin-1 Receptor Antagonist, Nature, 343:341-346 (1990) | |
| | C53 | ELLISON et al., The Nucleotide Sequence of A Human Immunoglobulin Cy1 Gene, Nucleic Acids Res. 10(13): 4071-79 (1982) | |
| | C54 | ESMON, The Roles of Protein C and Thrombomodulin in the Regulation of Blood Coagulation, J. Biol. Chem., 264:4743-4746 (1989) | |
| | C55 | European Search Report for EP 97 12 0664, dated 3/9/98 | |
| | C56 | FELL et al., Genetic Construction And Characterization Of A Fusion Protein Consisting Of A Chimeric F(ab') With Specificity For Carcinomas And Human IL-2, J. Immunol., 146:2446-2452 (1991) | |
| | C57 | FERNANDEZ-BOTRAN et al., A Soluble, High-Affinity, Interleukin-4-Binding Protein is Present in the Biological Fluids of Mice, Proc. Natl. Acad. Sci., 87:4202-4206 (1990) | |
| | C58 | FERNANDEZ-BOTRAN, Soluble Cytokine Receptors: Their Role in Immunoregulation, The FASEB Journal, 5:2567-2574 (1991) | |
| | C59 | FERRANTE et al., Inhibition of Tumour Necrosis Factor Alpha (TNF- α)-Induced Neutrophil Respiratory Burst by a TNF Inhibitor, Immunology, 72:440-442 (1991) | |
| | C60 | FISHER et al., Cloning And Expression Of Human Tissue Factor cDNA, Thrombosis Research, 48:89-99 (1987) | |
| | C61 | FISHER et al., Treatment of Septic Shock with the Tumor Necrosis Factor Receptor: Fc Fusion Protein, New Eng. J. Med., 334:1697-1702 (1996) | |
| | C62 | FOLEY et al., An Inhibitor of the Toxicity of Tumour Necrosis Factor in the Serum of Patients With Sarcoidosis, Tuberculosis and Crohn's Disease, Clin. Exp. Immunol., 80:395-399 (1990) | |
| | C63 | FOMSGAARD et al., Preliminary Study on Treatment of Septic Shock Patients With Antilipopolysaccharide IgG from Blood Donors, Scand. J. Infect. Dis., 21:697-708 (1989) | |
| | C64 | GARCIA et al., High Sensitivity of Transgenic Mice Expressing Soluble TNFR1 Fusion Protein to Mycobacterial Infections: Synergistic Action of TNF and IFN- γ in the Differentiation of Protective Granulomas, Eur. J. Immunol., 27:3182-3190 (1997) | |
| | C65 | GASCOIGNE et al., Secretion of a Chimeric T-Cell Receptor-Immunoglobulin Protein, Proc. Natl. Acad. Sci USA, 84:2936-2940 (1987) | |
| | C66 | GEHR et al., Both Tumor Necrosis Factor Receptor Types Mediate Proliferative Signals In Human Mononuclear Cell Activation, J. Immunol., 149:911-917 (1992). | |
| | C67 | GILLIES et al., Targeting Human Cytotoxic T Lymphocytes To Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells, J. Immunol., 144:1067-1071 (1991) | |
| | C68 | GOODMAN, Identification of Antigenic Determinants, in Basic & Clinical Immunol., 24-25 (1982) | |
| | C69 | GOODMAN, Immunogenicity & Antigenic Specificity, in Basic & Clinical Immunol., 101-108 (1991) | |
| | C70 | GOODWIN et al., Molecular cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor, Molecular and Cellular Biology, 11:3020-3026 (1991) | |
| | C71 | GRAY et al, Cloning and Expression of cDNA for Human Lymphotoxin, a Lymphokine With Tumour Necrosis Activity, Nature, 312:721-724 (1984) | |
| | C72 | GRAY et al., Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein, Proc. Natl. Acad. Sci. 87: 7380-84 (1990) | |
| | C73 | GRUNDMANN et al., Characterization of cDNA Coding for Human Factor XIIIa, Proc. Natl. Acad. Sci. USA, 83:8024-8028 (1986) | |
| ✓ | C74 | HAAK-FRENDSCHO et al., Inhibition of TNF by a TNF Receptor Immunoadhesin, J. Immunol., 152:1347-1353 (1994) | |

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 3/1/02 |
|--------------------|--|-----------------|--------|




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | | | | |
|---|---|--------------------------|------------------------|------------------------|--------------|
| Substitute for form 1449A/B/PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 08/444,791-Conf. #5613 | | |
| | | Filing Date | May 19, 1995 | | |
| | | First Named Inventor | Brockhaus | | |
| | | Art Unit | 1644 | | |
| | | Examiner Name | R. Schwadron, Ph.D. | | |
| Sheet | 5 | of | 8 | Attorney Docket Number | 01017/40451C |

| | | |
|-----|-----|--|
| (m) | C75 | HANNUM et al., Interleukin-1 Receptor Antagonist Activity of a Human Interleukin-1 Inhibitor, Nature, 343:336-340 (1990) |
| | C76 | HEFLIN et al., Prevention by Granulocyte Depletion of Increased Vascular Permeability of Sheep Lung Following Endotoxemia, J. Clin. Invest., 68:1253-1260 (1981). |
| | C77 | HELLER et al., Amplified Expression of Tumor Necrosis Factor Receptor in Cells Transfected With Epstein-Barr Virus Shuttle Vector cDNA Libraries, J. Biol. Chem., 265:5708-5717 (1990) |
| | C78 | HELLER et al., Amplified Expression of the Tumor Necrosis Factor Receptor in Lymphoblastoid Cells Transfected with HeLa Cell-CDNA Expression Abstract WA 142, Napa Valley Conference 1989 |
| | C79 | HIMMLER et al., Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein, DNA and Cell Biology, 9:705-715 (1990) |
| | C80 | HOBART, The Immune System: A Course on the Molecular and Cellular Basis of immunity, Blackwell Scientific Pubs, Page 7 (1975) |
| | C81 | HOLTMANN et al., Down Regulation of the Receptors For Tumor Necrosis Factor By Interleukin 1 and 4β-Phorbol-12-Myristate-13-Acetate, J. Immunol., 139:1161-1167 (1987). |
| | C82 | HSU et al., Differential Expression and Ligand Binding Properties of Tumor Necrosis Factor Receptor Chimeric Mutants, J. Biol. Chem., 268:16430-16436 (1992) |
| | C83 | IDZERDA et al., Human Interleukin 4 Receptor Confers Biological Responsiveness And Defines A Novel Receptor Superfamily, J. Exp. Med., 171:861-873 (1990) |
| | C84 | IMAMURA et al., Expression Of Tumor Necrosis Factor Receptors On Human Monocytes And Internalization Of Receptor Bound Ligand, J. Immunol., 139:2989-2992 (1987) |
| | C85 | ISHIKURA et al., Differential Biologic Effects Resulting From Bimodal Binding of Recombinant Human Tumor Necrosis Factor to Myeloid Leukemia Cells, Blood, 73:419-424 (1989) |
| | C86 | ISRAEL et al., Binding Of Human TNF-α To High-Affinity Cell Surface Receptors: Effect Of IFN, Immunology Letters, 12:217-224 (1986) |
| | C87 | JACOBS et al., Pharmacokinetic Parameters and Biodistribution of Soluble Cytokine Receptors, International Review of Experimental Pathology, 34B:123-135 (1993) |
| | C88 | JONES et al, Structure of Tumour Necrosis Factor, Nature, 338:225-228 (1989) |
| | C89 | KACZMARSKI et al., The Cytokine Receptor Superfamily, Blood Reviews, 5:193-203 (1991) |
| | C90 | KAUSHANSKY, Structure-Function Relationships of the Hematopoietic Growth Factors, Proteins: Structure, Function & Genetics, 12:1-9 (1992) |
| | C91 | KEEGAN et al., The Interleukin-4 Receptor: Signal Transduction by a Hematopoietin Receptor, Journal of Leukocyte Biology, 55:272-279 (1994) |
| | C92 | KEEGAN et al., Interleukin 4 Receptor: Signaling Mechanisms, Immunology Today, 15:423-432 (1994) |
| | C93 | KLEINAU et al., Importance of CD23 for Collagen-Induced Arthritis: Delayed Onset and Reduced Severity in CD23-Deficient Mice, J. Immunol., 162:4266-4270 (1999) |
| | C94 | KLINKERT et al., TNF-α Receptor Fusion Protein Prevents Experimental Auto-Immune Encephalomyelitis and Demyelination in Lewis Rats: an Overview, The Journal of Neuroimmunology, 72:163-168 (1997). |
| | C95 | KOHNO et al., A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor, Proc. Natl. Acad. Sci. USA, 87:8331-8335 (1990) |
| | C96 | KRUSE et al., Conversion of Human Interleukin-4 Into a High Affinity Antagonist by a Single Amino Acid Replacement, The EMBO Journal, 11:3237-3244 (1992) |
| | C97 | KULL et al., Cellular Receptor for ¹²⁵ I-Labeled Tumor Necrosis Factor: Specific Binding, Affinity Labeling, and Relationship to Sensitivity, Proc. Natl. Acad. Sci. USA, 82:5756-5760 (1985) |
| ✓ | C98 | LANDOLFI, A Chimeric IL-2/Ig Molecule Possesses The Functional Activity Of Both Proteins, J. Immunol., 146:915-919 (1991) |

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 3/1/05 |
|--------------------|--|-----------------|--------|



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 08/444,791-Conf. #5613 |
| | | | | Filing Date | May 19, 1995 |
| | | | | First Named Inventor | Brockhaus |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | R. Schwadron, Ph.D. |
| Sheet | 6 | of | 8 | Attorney Docket Number | 01017/40451C |

| | | | |
|-----|------|--|--|
| (M) | C99 | LANGNER et al., Structural and Functional Analysis of a TNF Receptor-Immunoglobulin Fusion Protein, New Advances on Cytokines, 349-354 (1992) | |
| | C100 | LEBERTHON et al., Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate, Cancer Research, 51:2694-2698 (1991) | |
| | C101 | LESSLAUER et al., Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice From Lipopolysaccharide-Induced Lethality, Eur. J. Immunol., 21:2883-2886 (1991) | |
| | C102 | LIABAKK et al., A Rapid and Sensitive Immunoassay for Tumor Necrosis Factor Using Magnetic Monodisperse Polymer Particles, Journal of Immunological Methods, 134:253-259 (1990) | |
| | C103 | LOETSCHER et al., Efficacy of a Chimeric TNFR-IgG Fusion Protein to Inhibit TNF Activity in Animal Models of Septic Shock, Endotoxin Research Series, 2:455-462 (1993) | |
| | C104 | LOETSCHER et al., Two distinct human TNF receptors: purification, molecular cloning and expression, in Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application, (3 rd International Conference | |
| | C105 | MALISZEWSKI et al., Cytokine Receptors And B Cell Functions: Recombinant Soluble Receptors Specifically Inhibit IL-1 and IL-4 Induced Cell Activities In Vitro, J. Immunol., 144:3028-3033 (1990) | |
| | C106 | MOHLER et al., Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists, J. Immunol., 151:1548-1561 (1993) | |
| | C107 | MORI et al., Attenuation of Collagen-Induced Arthritis in 55-kDa TNF Receptor Type 1 (TNFR1)-IgG1-Treated and TNFR1-Deficient Mice, J. Immunol., 157:3178-3182 (1996) | |
| | C108 | MORRISSEY et al., Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade, Cell, 50:129-135 (1987) | |
| | C109 | MORRISON, In Vitro Antibodies: Strategies for Production and Application, Annu. Rev. Immunol., 10:239-265 (1992) | |
| | C110 | MOSLEY et al., The Murine Interleukin-4 Receptor: Molecular Cloning and Characterization of Secreted and Membrane Bound Forms, Cell, 59:335-348 (1989) | |
| | C111 | NOPHAR et al., Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor, The EMBO Journal, 9:3269-3278 (1990) | |
| | C112 | NOVOTNY et al., A Soluble, Single-Chain T-Cell Receptor Fragment Endowed With Antigen-Combining Properties, Proc. Natl. Acad. Sci. USA, 88:8646-8650 (1991) | |
| | C113 | OKAYAMA et al., High-Efficiency Cloning of Full-Length cDNA, Molecular and Cellular Biology, 2:161-170 (1982) | |
| | C114 | OKAYAMA et al., A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells, Molecular and Cellular Biology, 3:280-289 (1983) | |
| | C115 | OLD, Tumor Necrosis Factor, 2nd Intl Conference on Tumor Necrosis Factor & Related Cytokines, Napa, CA, 1-30 (1989) | |
| | C116 | PABORSKY et al., Purification of Recombinant Human Tissue Factor, Biochemistry, 28:8072-8077 (1989) | |
| | C117 | PARRILLO, Pathogenetic Mechanisms of Septic Shock, New Eng. J. Med., 328:1471-1477 (1993) | |
| | C118 | PEETRE et al., A Tumor Necrosis Factor Binding Protein is Present in Human Biological Fluids, Eur. J. Haematol. 41:414-419 (1988) | |
| | C119 | PENNICA et al., Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin, Nature, 312:724-729 (1984) | |
| | C120 | PEPPEL et al., Chimaeric TNF-Receptor - IgG Molecule Acts As Soluble Inhibitor Of TNF Mediated Cytotoxicity, J. Cell. Biochem., Supp. 15F:439 (1991) | |

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 3/1/07 |
|--------------------|--|-----------------|--------|



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 08/444,791-Conf. #5613 |
| | | | | Filing Date | May 19, 1995 |
| | | | | First Named Inventor | Brockhaus |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | R. Schwadron, Ph.D. |
| Sheet | 7 | of | 8 | Attorney Docket Number | 01017/40451C |

| | | | |
|-------|------|--|--|
| (295) | C121 | PIGUET et al., Evolution of Collagen Arthritis in Mice is Arrested by Treatment With Anti-Tumor Necrosis (TNF) Antibody or a Recombinant Soluble TNF Receptor, Immunology, 77 (4):510-514 (1992) | |
| | C122 | REDFIELD et al., Secondary Structure and Topology of Human Interleukin 4 in Solution, Biochemistry, 30:11029-11035 (1991) | |
| | C123 | RUBIN, Binding Receptor Characters Zako and Expression, and Intracellular Events. 2nd Intl Conference on Tumor Necrosis Factor & Related Cytokines, Napa, CA, 94-96 (1989) | |
| | C124 | RUDDLE et al., An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis, J. Exp. Med., 172:1193-1200 (1990) | |
| | C125 | RUTKA et al., The Effects of Human Recombinant Tumor Necrosis Factor on Glioma-Derived Cell Lines: Cellular Proliferation, Cytotoxicity, Morphological and Radioreceptor Studies, Int. J. Cancer., 41:573-582 (1988) | |
| | C126 | SAXNE et al., Detection of Tumor Necrosis Factor α But Not Tumor Necrosis Factor β in Rheumatoid Arthritis Synovial Fluid and Serum, Arthritis & Rheumatism, 31:1041-1045 (1988) | |
| | C127 | SCALLON et al., Functional Comparisons Of Different Tumour Necrosis Factor Receptor/IgG Fusion Proteins, Cytokine, 7:759-770 (1995) | |
| | C128 | SCARPATI et al., Human Tissue Factor: cDNA Sequence and Chromosome Localization of the Gene, Biochemistry, 26:5234-5238 (1987) | |
| | C129 | SCHLEIFFENBAUM et al., The Tumor Necrosis Factor Receptor and Human Neutrophil Function, J. Clin. Invest., 86:184-195 (1990) | |
| | C130 | SCHNEE et al., Construction and Expression of a Recombinant Antibody-Targeted Plasminogen Activator, Proc. Natl. Acad. Sci. USA, 84:6904-6908 (1987) | |
| | C131 | SECKINGER et al., A Human Inhibitor Of Tumor Necrosis Factor α , J. Exp. Med. 167:1511-1516 (1988) | |
| | C132 | SHALABY et al., Receptor Binding and Activation of Polymorphonuclear Neutrophils by Tumor Necrosis Factor-Alpha, Journal of Leukocyte Biology, 41:196-204 (1987) | |
| | C133 | SHALABY et al., Binding and Regulation of Cellular Function by Monoclonal antibodies Against Human Tumor Necrosis Factor Receptors, J. Exp. Med. 172: 1517-1520 (1990) | |
| | C134 | SHEEHAN et al., Generation and Characterization of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors, Journal of Immunology, 142:3884-3893 (1989) | |
| | C135 | SHIN et al., Expression and Characterization of an Antibody Binding Specificity Joined to Insulin-Like Growth Factor 1: Potential Applications for Cellular Targeting, Proc. Natl. Acad. Sci., 87:5322-5326 (1990) | |
| | C136 | SIMS et al., cDNA Expression Cloning of the IL-1 Receptor, a Member of the Immunoglobulin Superfamily, Science, 241:585-589 (1988). | |
| | C137 | SIMS et al., Cloning the Interleukin 1 Receptor From Human T Cells, Proc. Natl. Acad. Sci., 86:8946-8950 (1989) | |
| | C138 | SMITH et al., The Active Form of Tumor Necrosis Factor Is a Trimer, J. Biol. Chem., 262:6951-6954 (1987) | |
| | C139 | SMITH et al., Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen, Science, 238:1704-1707 (1987) | |
| | C140 | SMITH et al., Multimeric Structure of the Tumor Necrosis Factor Receptor of HeLa Cells, J. Biol. Chem., 264:14646-14652 (1989) | |
| | C141 | SPICER et al., Isolation of cDNA Clones Coding for Human Tissue Factor: Primary Structure of the Protein and cDNA, Proc. Natl. Acad. Sci., 84:5148-5152 (1987) | |
| | C142 | STAINES et al., Collagen Arthritis-What Can It Teach Us?, British Journal of Rheumatology, 33:798-807 (1994) | |
| | C143 | STRADER et al., Structural Basis of β -Adrenergic Receptor Function, The FASEB Journal, 3:1825-1832 (1989) | |

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 3/1/02 |
|--------------------|--|-----------------|--------|



PTO/SB/08a/b (08-03)
 Approved for use through 07/31/2008. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Copyright Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|--|
| Substitute for form 1449A/B/PTO | | | Complete if Known | | |
| | | | Application Number | 08/444,791-Conf. #5613 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Filing Date | May 19, 1995 | |
| | | | First Named Inventor | Brockhaus | |
| | | | Art Unit | 1644 | |
| | | | Examiner Name | R. Schwadron, Ph.D. | |
| | | | Attorney Docket Number | 01017/40451C | |
| Sheet | 8 | of | 8 | | |

| | | | |
|-----|------|--|--|
| 125 | C144 | SUGGS et al., Use of Synthetic Oligonucleotides as Hybridization Probes: Isolation of Cloned cDNA Sequences for Human β_2 -Microglobulin, Proc. Natl. Acad. Sci. U.S.A., 78:6613-6617 (1981) | |
| | C145 | TAUBER et al., Toxicity in Neuronal Cells Caused by Cerebrospinal Fluid from Pneumococcal and Gram-Negative Meningitis, The Journal of Infectious Diseases, 166:1045-1050 (1992) | |
| | C146 | THOMA et al., Identification of a 60-kD Tumor Necrosis Factor (TNF) Receptor as the Major Signal Transducing Component in TNF Responses, J. Exp. Med. 172: 1019-23 (1990) | |
| | C147 | TSUJIMOTO et al., Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells, Archives of Biochemistry and Biophysics, 249:563-568 (1986) | |
| | C148 | TSUJIMOTO et al., Interferon- γ Enhances Expression of Cellular Receptors for Tumor Necrosis Factor, J. Immunol., 136:2441-2444 (1986) | |
| | C149 | TSUJIMOTO et al., Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells, Proc. Natl. Acad. Sci. 82: 7626-30 (1985) | |
| | C150 | ULICH et al., Intratracheal Administration of Endotoxin and Cytokines, Clinical Immunology & Immunopathology., 72:137-140 (1994) | |
| | C151 | UNGLAUB et al., Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators, J. Exp. Med. 166:1788-1797 (1987) | |
| | C152 | VAN DER POLL et al., Pretreatment with a 55-kDa Tumor Necrosis Factor Receptor-Immunoglobulin Fusion Protein Attenuates Activation of Coagulation, but not of Fibrinolysis, during Lethal Bacteremia in Baboons, The Journal of Infectious Diseases., 176:296-299 (1997) | |
| | C153 | VAN ZEE et al., Protection Against Lethal <i>Escherichia coli</i> Bacteremia in Baboons (<i>Papio anubis</i>) by Pretreatment With a 55-kDa TNF Receptor (CD120a)-Ig Fusion Protein, Ro 45-2081, J. Immunol., 156:2221-2230 (1996) | |
| | C154 | WALLACH et al., Soluble and Cell Surface Receptors for Tumor Necrosis Factor, Progress, Inflammation Research & Therapy, 51-57 (1991) | |
| | C155 | WALLACH et al., Cell surface and soluble TNF receptors, in Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application, (3 rd International Conference on Tumor Necrosis Factor and Related Cytokines, Makuhari, Chiba, Nov. 21-25, 1990), Osawa and Bonavida, eds., Basel, Karger, pp 47-57 (1992) | |
| | C156 | WILKS, The CD4 Receptor: Post Binding Events, Conformational Change and the Second Site, Molec. Aspects Med., 12:255-265 (1991) | |
| | C157 | YAMASAKI et al., Cloning and Expression of the Human Interleukin-6 (BSF-2/IFN β 2) Receptor, Science, 241:825-282 (1988). | |
| | C158 | YONEHARA et al., A Cell-Killing Monoclonal Antibody (Anti-Fas) to a Cell Surface Antigen Co-Downregulated With the Receptor of Tumor Necrosis Factor, J. Exp. Med., 169:1747-1765 (1989) | |
| | C159 | YOSHIE et al., Binding and Crosslinking of ¹²⁵ I-Labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors, J. Biochem., 100: 531-541(1986) | |
| | C160 | BROWER et al. Roche's RA Drug Crippled, Nature Biotechnology, 15:1325 (1997) | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 3/1/07 |
|--------------------|--|-----------------|--------|